当前位置:
首页
>
产品中心 >
monoclonal_antibody >
Hycult Biotech/JAM-A, Human, mAb BV16, FITC | Hycult Biotech/HM2098F-100UG
Hycult Biotech/JAM-A, Human, mAb BV16, FITC | Hycult Biotech/HM2098F-100UG
商品编号:
HM2098F-100UG
品牌:
hycultbiotech
市场价:
¥9720.00
美元价:
5832.00
产品分类:
单克隆抗体
公司分类:
monoclonal_antibody
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
The FITC conjugated monoclonal antibody BV16 recognizes the human junction adhesion molecule (JAM)-A. Together with JAM-C (JAM-2) and JAM-B (VE-JAM or JAM-3), JAM-A belongs to a family of adhesion proteins with a V-C2 immunoglobulin domain organization and their molecular weight is about 30-40 kDa. JAMs are important for a variety of cellular processes, including tight junction assembly, leukocyte transmigration, platelet activation, angiogenesis and virus binding. JAM-A is expressed by endothelial and epithelial cells, platelets, neutrophils, monocytes, lymphocytes and erythrocytes. Like all other JAMs, JAM-A plays an important role in tight junctions where it is involved in cell-to-cell adhesion through homophilic interaction. It codistributes with other tight junction components as ZO-1, 7H6 antigen, cingulin and occludin. JAM-A also plays an important role in leukocyte transmigration. Leukocyte transmigration can be blocked by antibodies and by soluble JAM-A/Fc fusion proteins. Homophilic JAM-A interactions between leukocytes and the endothelium but also heterophilic interactions of JAM-A with the beta 2-integrin leukocyte function-associated antigen-1 (LFA-1) are considered to actively guide leukocytes during transmigration. Several studies imply a role for JAM-A in the initiation of atherosclerosis, since JAM-A is upregulated on early atherosclerotic endothelium. Adhesion of the activated platelets on activated endothelium is mediated by homophilic interactions of JAM-A.
品牌介绍
荷兰HyCult Biotechnology(HBT)位于荷兰乌登,从1994开始制造检测抗体和蛋白质,主要侧重与病理学诊断有关的全套产品研发,既有纯化的重组蛋白和多肽,也有单抗和多抗,是世界一流的先天免疫领域的研究试剂制造商。
联络我们